Alkem Laboratories Ltd
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
- Market Cap ₹ 56,833 Cr.
- Current Price ₹ 4,753
- High / Low ₹ 5,520 / 3,186
- Stock P/E 33.7
- Book Value ₹ 823
- Dividend Yield 0.73 %
- ROCE 13.7 %
- ROE 12.1 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 36.0%
Cons
- Promoter holding has decreased over last 3 years: -3.42%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2,011 | 2,485 | 3,113 | 3,674 | 4,905 | 5,688 | 6,401 | 7,357 | 8,344 | 8,865 | 10,634 | 11,599 | 12,634 | |
1,645 | 2,123 | 2,700 | 3,248 | 4,038 | 4,687 | 5,392 | 6,237 | 6,868 | 6,920 | 8,580 | 9,977 | 10,438 | |
Operating Profit | 366 | 362 | 413 | 427 | 866 | 1,001 | 1,009 | 1,120 | 1,476 | 1,945 | 2,054 | 1,622 | 2,197 |
OPM % | 18% | 15% | 13% | 12% | 18% | 18% | 16% | 15% | 18% | 22% | 19% | 14% | 17% |
154 | 167 | 162 | 176 | 227 | 110 | 115 | 82 | 102 | 230 | 146 | 101 | 79 | |
Interest | 58 | 88 | 93 | 81 | 71 | 45 | 55 | 55 | 65 | 59 | 52 | 107 | 115 |
Depreciation | 29 | 40 | 52 | 71 | 93 | 101 | 143 | 193 | 253 | 275 | 304 | 310 | 294 |
Profit before tax | 433 | 402 | 430 | 451 | 928 | 965 | 926 | 955 | 1,260 | 1,842 | 1,844 | 1,305 | 1,867 |
Tax % | 6% | 4% | -1% | 13% | 19% | 6% | 31% | 19% | 9% | 12% | 9% | 23% | |
407 | 384 | 435 | 392 | 752 | 905 | 638 | 774 | 1,149 | 1,618 | 1,680 | 1,007 | 1,575 | |
EPS in Rs | 340.02 | 321.01 | 364.10 | 32.75 | 62.02 | 74.61 | 52.77 | 63.61 | 94.26 | 132.57 | 137.63 | 82.31 | 131.58 |
Dividend Payout % | 6% | 6% | 5% | 12% | 20% | 20% | 25% | 25% | 27% | 23% | 25% | 61% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | 13% |
3 Years: | 12% |
TTM: | 13% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | -2% |
TTM: | 64% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 23% |
3 Years: | 19% |
1 Year: | 38% |
Return on Equity | |
---|---|
10 Years: | 18% |
5 Years: | 18% |
3 Years: | 18% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
Reserves | 1,802 | 2,160 | 2,567 | 2,975 | 3,668 | 4,444 | 4,840 | 5,415 | 6,137 | 7,353 | 8,614 | 9,021 | 9,819 |
1,007 | 1,552 | 1,128 | 1,306 | 658 | 659 | 998 | 944 | 1,616 | 1,792 | 2,668 | 1,397 | 1,441 | |
644 | 547 | 604 | 986 | 1,184 | 1,440 | 1,803 | 1,824 | 2,169 | 2,351 | 2,763 | 3,315 | 3,642 | |
Total Liabilities | 3,466 | 4,271 | 4,311 | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 14,926 |
919 | 1,072 | 1,170 | 1,374 | 1,450 | 1,797 | 2,284 | 2,530 | 2,908 | 2,793 | 2,902 | 2,683 | 2,905 | |
CWIP | 0 | 0 | 0 | 111 | 172 | 299 | 381 | 493 | 363 | 393 | 339 | 323 | 181 |
Investments | 323 | 478 | 588 | 481 | 509 | 553 | 444 | 324 | 261 | 333 | 371 | 622 | 626 |
2,224 | 2,721 | 2,553 | 3,325 | 3,403 | 3,918 | 4,555 | 4,861 | 6,413 | 8,000 | 10,457 | 10,129 | 11,214 | |
Total Assets | 3,466 | 4,271 | 4,311 | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 14,926 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
159 | 78 | 290 | 325 | 726 | 471 | 266 | 780 | 585 | 1,265 | 1,111 | 1,682 | |
-246 | -403 | 353 | -235 | 205 | -294 | -351 | -318 | -737 | -995 | -1,433 | 120 | |
-11 | 356 | -600 | -52 | -927 | -138 | 85 | -379 | 79 | -272 | 380 | -1,761 | |
Net Cash Flow | -98 | 31 | 44 | 39 | 3 | 40 | 0 | 82 | -73 | -2 | 58 | 42 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 45 | 47 | 43 | 52 | 42 | 46 | 62 | 62 | 72 | 66 | 65 | 67 |
Inventory Days | 168 | 191 | 163 | 169 | 169 | 198 | 221 | 186 | 198 | 241 | 262 | 194 |
Days Payable | 121 | 99 | 81 | 101 | 108 | 122 | 147 | 119 | 104 | 112 | 102 | 87 |
Cash Conversion Cycle | 92 | 139 | 126 | 121 | 103 | 122 | 135 | 129 | 167 | 196 | 225 | 174 |
Working Capital Days | 63 | 96 | 74 | 60 | 48 | 65 | 84 | 88 | 109 | 117 | 120 | 107 |
ROCE % | 19% | 15% | 14% | 12% | 23% | 21% | 17% | 16% | 18% | 22% | 18% | 14% |
Documents
Announcements
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 1d
-
Intimation Under Regulation 30 Of SEBI LODR - Regulatory Order
16 Apr - The Company has received an order passed by statutory authority under Goods and Services Tax Act, 2017. The relevant disclosure is enclosed herewith.
- Reply To BSE Email - Additional Details Required Under SEBI Circular Dated July 13, 2023, For Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations, 2015. 12 Apr
- Compliances- Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015 For The Year Ended 31St March, 2024. 11 Apr
-
Compliance Certificate For The Period Ended March, 2024.
10 Apr - With reference to the subject matter, please find enclosed herewith the Compliance Certificate under Regulation 7 (3) of SEBI (LODR) Regulations, 2015, duly signed by …
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptPPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Aug 2019Transcript PPT
-
May 2019Transcript PPT
-
Feb 2019TranscriptPPT
-
Oct 2018TranscriptPPT
-
Jul 2018TranscriptPPT
-
May 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017Transcript PPT
-
Jan 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016Transcript PPT
-
May 2016TranscriptPPT
-
Feb 2016Transcript PPT
Leading Pharmaceutical company[1] Alkem is the fifth largest player in domestic formulation market with a market share of 3.9% as on March 31, 2022.
It has established its leadership position in acute therapy, with a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutrient segments.